Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

Literature DB >> 30782386

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

Karim Rihawi¹, Diana Giannarelli², Domenico Galetta³, Angelo Delmonte⁴, Marco Giavarra⁵, Daniele Turci⁶, Marina Garassino⁷, Marcello Tiseo⁸, Fausto Barbieri⁹, Stefano Panni¹⁰, Andrea Ardizzoni¹¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2019 PMID： 30782386 DOI： 10.1016/j.jtho.2018.11.036

Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.

Authors: J Nicholas Bodor; Jessica R Bauman; Elizabeth A Handorf; Eric A Ross; Margie L Clapper; Joseph Treat
Journal: J Cancer Res Clin Oncol Date: 2022-06-16 Impact factor: 4.322

2. Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers.

Authors: Yonina R Murciano-Goroff; Terry Pak; Sebastian Mondaca; Jessica R Flynn; Joseph Montecalvo; Natasha Rekhtman; Darragh Halpenny; Andrew J Plodkowski; Stephanie L Wu; Mark G Kris; Paul K Paik; Gregory J Riely; Helena A Yu; Charles M Rudin; Matthew D Hellmann; Josiah D Land; Larry W Buie; Glenn Heller; Piro Lito; Rona Yaeger; Alexander Drilon; Dazhi Liu; Bob T Li; Michael Offin
Journal: Br J Cancer Date: 2021-12-28 Impact factor: 9.075

3. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors: Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal: Transl Lung Cancer Res Date: 2021-06

4. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer  with Rare Mutation].

Authors: Teng Li; Junling Li
Journal: Zhongguo Fei Ai Za Zhi Date: 2021-01-20

Review 5. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

Authors: Ichidai Tanaka; Masahiro Morise
Journal: Int J Mol Sci Date: 2021-12-27 Impact factor: 5.923

Review 10. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant  Advanced Non-small Cell Lung Cancer].

Authors: Na Li; Yanjun Xu; Yun Fan
Journal: Zhongguo Fei Ai Za Zhi Date: 2021-10-20

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

1. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.

2. Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers.

3. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

4. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer  with Rare Mutation].

Review 5. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

6. Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study.

Review 7. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR.

Review 8. Treatment of Rare Mutations in Patients with Lung Cancer.

9. [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation  in Non-small Cell Lung Cancer].

Review 10. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant  Advanced Non-small Cell Lung Cancer].

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.

1. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.

2. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers.

3. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

4. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation].

Review 5. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

6. Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study.

Review 7. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR.

Review 8. Treatment of Rare Mutations in Patients with Lung Cancer.

9. [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer].

Review 10. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer].

2. Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers.

4. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer  with Rare Mutation].

9. [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation  in Non-small Cell Lung Cancer].

Review 10. [Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant  Advanced Non-small Cell Lung Cancer].